Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Hong

Showing results (241-250 of 442) with videos related to

Pageof 45
Sort By:
Oncotarget|July 10, 2015
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumorsDavid S Hong, Peter Rosen, A Craig Lockhart, et al.
Investigational New Drugs|November 4, 2014
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumorsGerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Journal of Hematology & Oncology|January 1, 2020
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicineApostolia-Maria Tsimberidou, David S Hong, Jennifer J Wheler, et al.
Investigational New Drugs|November 27, 2012
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumorsDavid S Hong, Jennifer Hsing Choe, Aung Naing, et al.
Oncotarget|July 13, 2015
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trialsIshwaria M Subbiah, Gerald S Falchook, Ahmed O Kaseb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2012
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiativeApostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid TumorsDavid S Hong, Olivier Rixe, Vi K Chiu, et al.
Oncotarget|September 22, 2018
Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinicVikas Dembla, Neeta Somaiah, Pedro Barata, et al.
Signal Transduction and Targeted Therapy|February 23, 2026
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncologyStephanie T Schmidt, Mehmet A Baysal, Siqing Fu, et al.
Investigational New Drugs|October 18, 2014
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancerGerald S Falchook, Stacy Moulder, Aung Naing, et al.
Pageof 45

Showing results (241-250 of 442) with videos related to

Sort By:
Pageof 45
Oncotarget|July 10, 2015
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumorsDavid S Hong, Peter Rosen, A Craig Lockhart, et al.
Investigational New Drugs|November 4, 2014
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumorsGerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Journal of Hematology & Oncology|January 1, 2020
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicineApostolia-Maria Tsimberidou, David S Hong, Jennifer J Wheler, et al.
Investigational New Drugs|November 27, 2012
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumorsDavid S Hong, Jennifer Hsing Choe, Aung Naing, et al.
Oncotarget|July 13, 2015
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trialsIshwaria M Subbiah, Gerald S Falchook, Ahmed O Kaseb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2012
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiativeApostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid TumorsDavid S Hong, Olivier Rixe, Vi K Chiu, et al.
Oncotarget|September 22, 2018
Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinicVikas Dembla, Neeta Somaiah, Pedro Barata, et al.
Signal Transduction and Targeted Therapy|February 23, 2026
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncologyStephanie T Schmidt, Mehmet A Baysal, Siqing Fu, et al.
Investigational New Drugs|October 18, 2014
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancerGerald S Falchook, Stacy Moulder, Aung Naing, et al.
Pageof 45